This project studies the dynamics of the VOR as an adaptive control system during the compensation periods of selected patients and the normal subjects undergoing high--fequency testing. The gain and phase of the horizontal and vertical vestibulo--ocular reflex (VOR) were determined at higher frequencies (2--6 Hz) using a protocal based on active head movements called the Vestibular Autorotation Test (VAT). Progress in this project focused on three areas: 1) Nonparametric gains and phases of patients with balance disorders, used for graphical comparison with normative data, 2) Parametric modeling using Auto--Regressive--Moving--Average (ARMA) methods, and 3) Block--structured modeling of the high--frequency horizontal and vertical VORs. Characteristics describing the gain and phase (vestibulograms), of the horizontal and vertical VOR were used to provide clinicians with patterns useful for determining diagnoses and to monitor changes in the VORs of patients with vestibular disorders undergoing treatment, i.e., ``balance retraining''. This treatment is based on using the brain's natural adaptive capabilities to respond to specific exercise therapy to alleviate symptoms of dysequilibrium. Parametric modeling of the VOR was done through ARMA modeling of patient data. Specific patient populations (e.g., Meniere's disease, gentamicin ototoxicity) were targeted to determine the ranges for parameters of a specific disease, and the parametric changes during therapeutic treatments which activated the adaptive control reduction of retinal--slip error signals in the VOR. Results showed significant differences from normal control groups. Results from specific disease categories are described below in collaborative studies. A new method was developed which provides quantitative predictions of future VOR parametric changes during clinical therapeutic treatment.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Biotechnology Resource Grants (P41)
Project #
5P41RR001861-12
Application #
5223745
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
12
Fiscal Year
1996
Total Cost
Indirect Cost
Song, Dong; Wang, Haonan; Tu, Catherine Y et al. (2013) Identification of sparse neural functional connectivity using penalized likelihood estimation and basis functions. J Comput Neurosci 35:335-57
Hoppenbrouwers, Toke; Oliveira, Flavia; Sandarupa, Stanislaus et al. (2012) The development of the circadian heart rate rhythm (CHR) in Asian infants. Early Hum Dev 88:555-61
Wang, Xiaoning; Schumitzky, Alan; D'Argenio, David Z (2007) Nonlinear Random Effects Mixture Models: Maximum Likelihood Estimation via the EM Algorithm. Comput Stat Data Anal 51:6614-6623
Gholmieh, Ghassan; Courellis, Spiros; Marmarelis, Vasilis et al. (2007) Nonlinear dynamic model of CA1 short-term plasticity using random impulse train stimulation. Ann Biomed Eng 35:847-57
Gholmieh, Ghassan; Courellis, Spiros; Dimoka, Angelika et al. (2004) An algorithm for real-time extraction of population EPSP and population spike amplitudes from hippocampal field potential recordings. J Neurosci Methods 136:111-21
Ashjian, Peter; Elbarbary, Amir; Zuk, Patricia et al. (2004) Noninvasive in situ evaluation of osteogenic differentiation by time-resolved laser-induced fluorescence spectroscopy. Tissue Eng 10:411-20
Jo, Javier A; Blasi, Anna; Valladares, Edwin et al. (2003) Model-based assessment of autonomic control in obstructive sleep apnea syndrome during sleep. Am J Respir Crit Care Med 167:128-36
Belozeroff, Vasily; Berry, Richard B; Khoo, Michael C K (2003) Model-based assessment of autonomic control in obstructive sleep apnea syndrome. Sleep 26:65-73
Bading, James R; Yoo, Paul B; Fissekis, John D et al. (2003) Kinetic modeling of 5-fluorouracil anabolism in colorectal adenocarcinoma: a positron emission tomography study in rats. Cancer Res 63:3667-74
Xu, Lu; Eiseman, Julie L; Egorin, Merrill J et al. (2003) Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite in tumor-bearing mice. J Pharmacokinet Pharmacodyn 30:185-219

Showing the most recent 10 out of 84 publications